6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders

US9328120B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Niklas Heine · Eberhardzell, DE
• Christian Eickmeier · Mittelbiberach, DE
• Marco Ferrera · San Donato Milanese, IT
• Riccardo Giovannini · Verona, IT
• Holger Rosenbrock · Mittelbiberach, DE
• Gerhard Schaenzle · Biberach, DE

Key dates

• Filing date: Oct 10, 2014
• Grant date: May 3, 2016
• Expiry date: Oct 10, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel 6-Cycloalkyl-pyrazolopyrimidinones according to formula (I).wherein R1 is a 5 or 6 membered aromatic heteroaryl-group, R2 is an optional substituent, D is optionally substituted cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl or 2-, 3- or 4-pyridyl, m=1 or 2 and n is 0, 1 or 2.The new compounds are for use as the active entity of medicaments or for the manufacture of medicaments respectively, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. Such conditions may for example be associated with Alzheimer's disease, schizophrenia and other diseases. The new compounds are also for example for the manufacture of medicaments and/or for use in the treatment of these diseases, in particular for cognitive impairment associated with such disease. The compounds of the invention show PDE9 inhibiting properties.